Liquidia (NASDAQ:LQDA) Stock: Insider Sarah Krepp Sells 5,245 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 5,245 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $149,377.60. Following the sale, the insider owned 115,241 shares of the company’s stock, valued at approximately $3,282,063.68. This represents a 4.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Trading Down 3.1%

Shares of LQDA stock traded down $0.86 during mid-day trading on Tuesday, reaching $26.81. The company’s stock had a trading volume of 3,092,611 shares, compared to its average volume of 5,078,983. The company’s 50 day simple moving average is $63.40 and its 200-day simple moving average is $61.76. Liquidia Corporation has a 12-month low of $21.94 and a 12-month high of $93.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $2.40 billion, a PE ratio of 19.57 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same quarter in the previous year, the firm posted ($0.49) EPS. The business’s revenue was up 1842.1% compared to the same quarter last year. On average, research analysts predict that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Institutional Trading of Liquidia

A number of hedge funds and other institutional investors have recently modified their holdings of LQDA. Bank of America Corp DE increased its position in shares of Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after acquiring an additional 360,372 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Liquidia in the second quarter valued at about $29,694,000. Eversept Partners LP boosted its holdings in Liquidia by 33.0% in the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after purchasing an additional 167,949 shares during the last quarter. Seven Fleet Capital Management LP grew its stake in Liquidia by 25.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after purchasing an additional 51,727 shares in the last quarter. Finally, Pale Fire Capital SE grew its stake in Liquidia by 2.4% during the 1st quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock valued at $14,657,000 after purchasing an additional 8,985 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Wall Street Analysts Forecast Growth

A number of research analysts have commented on LQDA shares. Stephens set a $130.00 price objective on Liquidia in a research note on Friday, July 24th. Wedbush set a $58.00 target price on Liquidia in a research note on Friday, October 2nd. Wells Fargo & Company reiterated an “equal weight” rating and set a $30.00 target price (down from $108.00) on shares of Liquidia in a report on Friday, October 2nd. Jefferies Financial Group upgraded Liquidia to a “strong-buy” rating in a report on Thursday, October 1st. Finally, Royal Bank Of Canada set a $130.00 target price on shares of Liquidia in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $83.69.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).